44,986 results match your criteria antitumor peptides

Formulation matters! A spectroscopic and molecular dynamics investigation on the peptide CIGB552 as itself and in its therapeutical formulation.

J Pept Sci 2021 Jun 10:e3356. Epub 2021 Jun 10.

PEPSA-LAB, Department of Chemical Sciences and Technology, University of Rome Tor Vergata, Rome, Italy.

Synthetic therapeutic peptides (STP) are intensively studied as new-generation drugs, characterized by high purity, biocompatibility, selectivity and stereochemical control. However, most of the studies are focussed on the bioactivity of STP without considering how the formulation actually used for therapy administration could alter the physico-chemical properties of the active principle. The aggregation properties of a 20-mer STP (Ac-His-Ala-Arg-Ile-Lys-D-Pro-Thr-Phe-Arg-Arg-D-Leu-Lys-Trp-Lys-Tyr-Lys-Gly-Lys-Phe-Trp-NH ), showing antitumor activity, were investigated by optical spectroscopy and atomic force microscopy imaging, as itself (CIGB552) and in its therapeutic formulation (CIGB552TF). Read More

View Article and Full-Text PDF

Electrochemistry of Quinones with Respect to their Role in Biomedical Chemistry.

Chem Rec 2021 Jun 9. Epub 2021 Jun 9.

Department of Chemistry, Ben-Gurion University of the Negev, Beer-Sheva, 84105, Israel.

Quinones are ubiquitous in nature and form one of the largest class of antitumor agents approved for clinical use. They are known to be efficient in inhibiting cancer cells growth. Under physiological conditions they can undergo non-enzymatic one-electron reduction to give the moderately toxic species of semiquinone radical-anion. Read More

View Article and Full-Text PDF

Viral Molecular Mimicry Influences the Antitumor Immune Response in Murine and Human Melanoma.

Cancer Immunol Res 2021 Jun 8. Epub 2021 Jun 8.

Laboratory of ImmunoViroTherapy, Drug Rfesearch Program, University of Helsinki

Molecular mimicry is one of the leading mechanisms by which infectious agents can induce autoimmunity. Whether a similar mechanism triggers an antitumor immune response is unexplored, and the role of antiviral T cells infiltrating the tumor has remained anecdotal. To address these questions, we first developed a bioinformatic tool to identify tumor peptides with high similarity to viral epitopes. Read More

View Article and Full-Text PDF

[Macrovipera lebetina obtusa Snake Venom as a Modulator of Antitumor Effect in S-180 Sarcoma Mouse Model].

Mol Biol (Mosk) 2021 May-Jun;55(3):468-477

Aging and Aneuploidy Laboratory, Institute de Biologia Molecular e Celular, Instituto de Investigação e Inavação em Saúde - i3S, Universidade do Porto, Porto, 4200-135 Portugal.

Macrovipera lebetina obtusa (MLO) is a venomous snake endemic to Middle East. Here we describe the therapeutic potential of the MLO snake venom. In S-180 sarcoma-bearing mouse model, we showed that the MLO snake venom inhibits tumour growth by 50%. Read More

View Article and Full-Text PDF

iAMP-CA2L: a new CNN-BiLSTM-SVM classifier based on cellular automata image for identifying antimicrobial peptides and their functional types.

Brief Bioinform 2021 Jun 4. Epub 2021 Jun 4.

University of Donja Gorica, Montenegro.

Predicting antimicrobial peptides (AMPs') function is an important and difficult problem, particularly when AMPs have many multiplex functions, i.e. some AMPs simultaneously have two or three functional classes. Read More

View Article and Full-Text PDF

STAT1 potentiates oxidative stress revealing a targetable vulnerability that increases phenformin efficacy in breast cancer.

Nat Commun 2021 06 3;12(1):3299. Epub 2021 Jun 3.

Department of Biochemistry, Microbiology and Immunology, Ottawa Institute of Systems Biology, University of Ottawa, Ottawa, ON, Canada.

Bioenergetic perturbations driving neoplastic growth increase the production of reactive oxygen species (ROS), requiring a compensatory increase in ROS scavengers to limit oxidative stress. Intervention strategies that simultaneously induce energetic and oxidative stress therefore have therapeutic potential. Phenformin is a mitochondrial complex I inhibitor that induces bioenergetic stress. Read More

View Article and Full-Text PDF

[pplication of Asn-Gly-Arg sequence based cyclic peptides for targeted tumor therapy].

Magy Onkol 2021 Jun 15;65(2):113-120. Epub 2021 May 15.

Kísérletes Farmakológiai Osztály, Országos Onkológiai Intézet, Budapest, Hungary.

The in vivo antitumor effect of two NGR sequence containing peptide-daunomycin conjugates was studied on CD13+ Kaposi's sarcoma s.c. tumor model on SCID mice, and on orthotopically developed CD13- HT-29 colon adenocarcinoma SCID mouse model. Read More

View Article and Full-Text PDF

Chitosan-Based Nanoparticles of Targeted Drug Delivery System in Breast Cancer Treatment.

Polymers (Basel) 2021 May 24;13(11). Epub 2021 May 24.

Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang 45363, Indonesia.

Breast cancer remains one of the world's most dangerous diseases because of the difficulty of finding cost-effective and specific targets for effective and efficient treatment methods. The biodegradability and biocompatibility properties of chitosan-based nanoparticles (ChNPs) have good prospects for targeted drug delivery systems. ChNPs can transfer various antitumor drugs to targeted sites via passive and active targeting pathways. Read More

View Article and Full-Text PDF

Marine Natural Products from Tunicates and Their Associated Microbes.

Mar Drugs 2021 May 26;19(6). Epub 2021 May 26.

Laboratoire de Chimie et Biotechnologie des Produits Naturels (CHEMBIOPRO), Université de La Réunion, ESIROI Agroalimentaire, 15 Avenue René Cassin, CS 92003, CEDEX 9, F-97744 Saint-Denis, Ile de La Réunion, France.

Marine tunicates are identified as a potential source of marine natural products (MNPs), demonstrating a wide range of biological properties, like antimicrobial and anticancer activities. The symbiotic relationship between tunicates and specific microbial groups has revealed the acquisition of microbial compounds by tunicates for defensive purpose. For instance, yellow pigmented compounds, "tambjamines", produced by the tunicate, (Sluiter, 1909), primarily originated from their bacterial symbionts, which are involved in their chemical defense function, indicating the ecological role of symbiotic microbial association with tunicates. Read More

View Article and Full-Text PDF

PPI Modulators of E6 as Potential Targeted Therapeutics for Cervical Cancer: Progress and Challenges in Targeting E6.

Molecules 2021 May 18;26(10). Epub 2021 May 18.

Department of Basic Sciences, Loma Linda University School of Medicine, 11021 Campus Street, 101 Alumni Hall, Loma Linda, CA 92354, USA.

Advanced cervical cancer is primarily managed using cytotoxic therapies, despite evidence of limited efficacy and known toxicity. There is a current lack of alternative therapeutics to treat the disease more effectively. As such, there have been more research endeavors to develop targeted therapies directed at oncogenic host cellular targets over the past 4 decades, but thus far, only marginal gains in survival have been realized. Read More

View Article and Full-Text PDF

Atovaquone Suppresses Triple-Negative Breast Tumor Growth by Reducing Immune-Suppressive Cells.

Int J Mol Sci 2021 May 13;22(10). Epub 2021 May 13.

Department of Biomedical Sciences, Texas Tech University Health Sciences Center, Amarillo, TX 79106, USA.

A major contributing factor in triple-negative breast cancer progression is its ability to evade immune surveillance. One mechanism for this immunosuppression is through ribosomal protein S19 (RPS19), which facilitates myeloid-derived suppressor cells (MDSCs) recruitment in tumors, which generate cytokines TGF-β and IL-10 and induce regulatory T cells (Tregs), all of which are immunosuppressive and enhance tumor progression. Hence, enhancing the immune system in breast tumors could be a strategy for anticancer therapeutics. Read More

View Article and Full-Text PDF

Targeting a cell surface vitamin D receptor on tumor-associated macrophages in triple-negative breast cancer.

Elife 2021 Jun 1;10. Epub 2021 Jun 1.

Rutgers Cancer Institute of New Jersey, Newark, United States.

Triple-negative breast cancer (TNBC) is an aggressive tumor with limited treatment options and poor prognosis. We applied the in vivo phage display technology to isolate peptides homing to the immunosuppressive cellular microenvironment of TNBC as a strategy for non-malignant target discovery. We identified a cyclic peptide (CSSTRESAC) that specifically binds to a vitamin D receptor, protein disulfide-isomerase A3 (PDIA3) expressed on the cell surface of tumor-associated macrophages (TAM), and targets breast cancer in syngeneic TNBC, non-TNBC xenograft, and transgenic mouse models. Read More

View Article and Full-Text PDF

Potential of peptide-engineered exosomes with overexpressed miR-92b-3p in anti-angiogenic therapy of ovarian cancer.

Clin Transl Med 2021 May;11(5):e425

Department of Gynecologic Oncology, Women's Hospital, School of Medicine, Zhejiang University, Hangzhou, Zhejiang, China.

Introduction: Exosomal microRNA (miRNA) as a mediator of intercellular communication plays an essential part in tumor-relevant angiogenesis. Therapy against angiogenesis has been demonstrated to have a remarkable antitumor efficacy in various malignancies, but not as expected in ovarian cancer.

Methods: Exosomes were isolated by ultracentrifugation. Read More

View Article and Full-Text PDF

A Combined Antitumor Strategy Mediated by a New Targeted Nanosystem to Hepatocellular Carcinoma.

Int J Nanomedicine 2021 18;16:3385-3405. Epub 2021 May 18.

CNC - Center for Neuroscience and Cell Biology (CNC), University of Coimbra, Coimbra, Portugal.

Background: Hepatocellular carcinoma (HCC) is one of the main causes of cancer-related death. Sorafenib, which is the first-line therapy for this disease, is associated with reduced therapeutic efficacy that could potentially be overcome by combination with selumetinib. In this context, the main goal of this work was to develop a new nanosystem, composed of a polymeric core coated by a lipid bilayer containing the targeting ligand GalNAc, to specifically and efficiently co-deliver both drugs into HCC cells, in order to significantly increase their therapeutic efficacy. Read More

View Article and Full-Text PDF

INPP4B promotes PI3Kα-dependent late endosome formation and Wnt/β-catenin signaling in breast cancer.

Nat Commun 2021 05 25;12(1):3140. Epub 2021 May 25.

Cancer Program, Biomedicine Discovery Institute, Monash University, Clayton, VIC, Australia.

INPP4B suppresses PI3K/AKT signaling by converting PI(3,4)P to PI(3)P and INPP4B inactivation is common in triple-negative breast cancer. Paradoxically, INPP4B is also a reported oncogene in other cancers. How these opposing INPP4B roles relate to PI3K regulation is unclear. Read More

View Article and Full-Text PDF

Influence of the Dabcyl group on the cellular uptake of cationic peptides: short oligoarginines as efficient cell-penetrating peptides.

Amino Acids 2021 May 25. Epub 2021 May 25.

Department of Organic Chemistry, Eötvös L. University, Pázmány P. Setany 1/A, Budapest, 1117, Hungary.

Cell-penetrating peptides (CPPs) are promising delivery vehicles. These short peptides can transport wide range of cargos into cells, although their usage has often limitations. One of them is the endosomatic internalisation and thus the vesicular entrapment. Read More

View Article and Full-Text PDF

Importance of early detection of infantile inflammatory bowel disease with defective IL-10 pathway: A case report.

Medicine (Baltimore) 2021 May;100(21):e25868

Department of Pediatric Gastroenterology, Hepatology and Nutrition, MacKay Children's Hospital, Taipei.

Rationale: Infantile inflammatory bowel disease (IBD) is an extremely rare subgroup of IBD that includes patients whose age of onset is younger than 2 years old. These patients can have more surgical interventions, and a severe and refractory disease course with higher rates of conventional treatment failure. Monogenic defects play an important role in this subgroup of IBD, and identification of the underlying defect can guide the therapeutic approach. Read More

View Article and Full-Text PDF

Supramolecular co-assembly of self-adjuvanting nanofibrious peptide hydrogel enhances cancer vaccination by activating MyD88-dependent NF-κB signaling pathway without inflammation.

Bioact Mater 2021 Nov 16;6(11):3924-3934. Epub 2021 Apr 16.

Tianjin Key Laboratory of Biomaterial Research, Institute of Biomedical Engineering, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, 300192, China.

Peptide vaccine targeting tumor-specific antigens is a promising cancer treatment regimen. However, peptide vaccines are commonly low-immunogenic, leading to suboptimal antitumor T-cell responses. Current peptide vaccination approaches are challenged by the variability of peptide physicochemical characters and vaccine formulations, flexibility, and the broad feasibility. Read More

View Article and Full-Text PDF
November 2021

Hyperactivation of HER2-SHCBP1-PLK1 axis promotes tumor cell mitosis and impairs trastuzumab sensitivity to gastric cancer.

Nat Commun 2021 05 14;12(1):2812. Epub 2021 May 14.

Cuiying Biomedical Research Center, Lanzhou University Second Hospital, Lanzhou, People's Republic of China.

Trastuzumab is the backbone of HER2-directed gastric cancer therapy, but poor patient response due to insufficient cell sensitivity and drug resistance remains a clinical challenge. Here, we report that HER2 is involved in cell mitotic promotion for tumorigenesis by hyperactivating a crucial HER2-SHCBP1-PLK1 axis that drives trastuzumab sensitivity and is targeted therapeutically. SHCBP1 is an Shc1-binding protein but is detached from scaffold protein Shc1 following HER2 activation. Read More

View Article and Full-Text PDF

Engineering T cells to enhance 3D migration through structurally and mechanically complex tumor microenvironments.

Nat Commun 2021 05 14;12(1):2815. Epub 2021 May 14.

Department of Biomedical Engineering, University of Minnesota, Minneapolis, Minnesota, USA.

Defining the principles of T cell migration in structurally and mechanically complex tumor microenvironments is critical to understanding escape from antitumor immunity and optimizing T cell-related therapeutic strategies. Here, we engineered nanotextured elastic platforms to study and enhance T cell migration through complex microenvironments and define how the balance between contractility localization-dependent T cell phenotypes influences migration in response to tumor-mimetic structural and mechanical cues. Using these platforms, we characterize a mechanical optimum for migration that can be perturbed by manipulating an axis between microtubule stability and force generation. Read More

View Article and Full-Text PDF

A cytokine receptor-masked IL2 prodrug selectively activates tumor-infiltrating lymphocytes for potent antitumor therapy.

Nat Commun 2021 05 13;12(1):2768. Epub 2021 May 13.

Department of Immunology, UT Southwestern Medical Center, Dallas, TX, 75390, USA.

As a potent lymphocyte activator, interleukin-2 (IL-2) is an FDA-approved treatment for multiple metastatic cancers. However, its clinical use is limited by short half-life, low potency, and severe in vivo toxicity. Current IL-2 engineering strategies exhibit evidence of peripheral cytotoxicity. Read More

View Article and Full-Text PDF

ZBP1 not RIPK1 mediates tumor necroptosis in breast cancer.

Nat Commun 2021 05 11;12(1):2666. Epub 2021 May 11.

National Cancer Institute; National Institutes of Health, Laboratory of Immune Cell Biology, Bethesda, MD, USA.

Tumor necrosis happens commonly in advanced solid tumors. We reported that necroptosis plays a major role in tumor necrosis. Although several key necroptosis regulators including receptor interacting protein kinase 1 (RIPK1) have been identified, the regulation of tumor necroptosis during tumor development remains elusive. Read More

View Article and Full-Text PDF

Selective and noncovalent targeting of RAS mutants for inhibition and degradation.

Nat Commun 2021 05 11;12(1):2656. Epub 2021 May 11.

Perlmutter Cancer Center, New York University Langone Health, New York, NY, USA.

Activating mutants of RAS are commonly found in human cancers, but to date selective targeting of RAS in the clinic has been limited to KRAS(G12C) through covalent inhibitors. Here, we report a monobody, termed 12VC1, that recognizes the active state of both KRAS(G12V) and KRAS(G12C) up to 400-times more tightly than wild-type KRAS. The crystal structures reveal that 12VC1 recognizes the mutations through a shallow pocket, and 12VC1 competes against RAS-effector interaction. Read More

View Article and Full-Text PDF

Adjuvant oncolytic virotherapy for personalized anti-cancer vaccination.

Nat Commun 2021 05 11;12(1):2626. Epub 2021 May 11.

CRCHUM: "Centre Hospitalier de l'Université de Montréal" Research Centre, Montreal, QC, Canada.

By conferring systemic protection and durable benefits, cancer immunotherapies are emerging as long-term solutions for cancer treatment. One such approach that is currently undergoing clinical testing is a therapeutic anti-cancer vaccine that uses two different viruses expressing the same tumor antigen to prime and boost anti-tumor immunity. By providing the additional advantage of directly killing cancer cells, oncolytic viruses (OVs) constitute ideal platforms for such treatment strategy. Read More

View Article and Full-Text PDF

A Stat1 bound enhancer promotes Nampt expression and function within tumor associated macrophages.

Nat Commun 2021 05 11;12(1):2620. Epub 2021 May 11.

Division of Microbiology and Immunology, Department of Pathology, University of Utah, Salt Lake City, UT, USA.

Tumor associated macrophage responses are regulated by distinct metabolic states that affect their function. However, the ability of specific signals in the local tumor microenvironment to program macrophage metabolism remains under investigation. Here, we identify NAMPT, the rate limiting enzyme in NAD salvage synthesis, as a target of STAT1 during cellular activation by interferon gamma, an important driver of macrophage polarization and antitumor responses. Read More

View Article and Full-Text PDF

Intratumoral bacteria generate a new class of therapeutically relevant tumor antigens in melanoma.

Cancer Cell 2021 May;39(5):601-603

Department of Bioengineering, University of California San Diego, La Jolla, CA, USA; Department of Pediatrics, University of California San Diego, La Jolla, CA, USA; Department of Computer Science and Engineering, University of California San Diego, La Jolla, CA, USA; Center for Microbiome Innovation, University of California San Diego, La Jolla, CA, USA. Electronic address:

The functional repertoire of intratumoral microorganisms and their local effects on the host remain poorly characterized. By revealing potentially immunogenic bacterial peptides on melanoma cells, a Nature paper provides evidence that intratumoral bacteria can directly modulate antitumor immune responses, and it details a new class of therapeutically relevant, non-human tumor antigens. Read More

View Article and Full-Text PDF

Amino acid sequence identification of goji berry cyclic peptides and anticervical carcinoma activity detection.

J Pept Sci 2021 May 6:e3326. Epub 2021 May 6.

Obstetrics and Gynecology Department, People's Hospital of Hekou District, Dongying, China.

The goji berry is widely used as tonics; however, the antihuman cervical carcinoma effect and underlying mechanism of goji berry peptide remain to be elucidated. The cyclic peptides are appealing targets in antitumor agent development, and in current study, three novel goji berry cyclic peptides (GCPs) were isolated and amino acid sequence identified. Among them, GCP-1 (Cycle-(Trp-Glu-His-Thr)) inhibited proliferation and induced human cervical cancer (HeLa) cells apoptosis and blocked the HeLa cells in G0/G1 phase significantly. Read More

View Article and Full-Text PDF

An Antibody-like Polymeric Nanoparticle Removes Intratumoral Galectin-1 to Enhance Antitumor T-Cell Responses in Cancer Immunotherapy.

ACS Appl Mater Interfaces 2021 May 6;13(19):22159-22168. Epub 2021 May 6.

Key Laboratory of Functional Polymer Materials of Ministry of Education, College of Chemistry, Nankai University, Tianjin 300071, China.

Antibodies have shown potential to deplete immunosuppressive factors in tumor tissues. However, intrinsic drawbacks, including time-consuming processes in preparation, high cost, and short half-life time, greatly restrict their applications. In this work, we report an antibody-like polymeric nanoparticle (APN) that is capable of specifically capturing and removing galectin-1 in tumor tissues, thereby enhancing the antitumor T-cell responses. Read More

View Article and Full-Text PDF

A TGFβ Signaling Inhibitor, SB431542, Inhibits Reovirus-mediated Lysis of Human Hepatocellular Carcinoma Cells in a TGFβ-independent Manner.

Anticancer Res 2021 May;41(5):2431-2440

Laboratory of Biochemistry and Molecular Biology, Graduate School of Pharmaceutical Sciences, Osaka University, Osaka, Japan;

Background/aim: Oncolytic reovirus, which is a non-enveloped virus possessing a 10-segmented double-stranded RNA genome, has been anticipated as a novel class of antitumor agent. Hepatocellular carcinoma (HCC) is considered to be a target suitable for reovirus-mediated virotherapy. Transforming growth factor (TGF)-β plays an important role in the pathogenesis of HCC. Read More

View Article and Full-Text PDF

Synergistic Effect of Bazedoxifene and PARP Inhibitor in the Treatment of Ovarian Cancer Regardless of BRCA Mutation.

Anticancer Res 2021 May;41(5):2277-2286

Department of Biochemistry and Molecular Biology, University of Maryland School of Medicine, Baltimore, MD, U.S.A.

Background/aim: Poly (ADP-ribose) polymerase inhibitors (PARPis) are one of the targeted therapies proven to treat breast cancer gene (BRCA)-mutant ovarian cancer. Because most ovarian cancers are BRCA wild-type, it is necessary to extend the usage of PARPis. In the present study, we combined the PARPi, talazoparib, and the IL-6 inhibitor, bazedoxifene, for the treatment of human ovarian cancer cells. Read More

View Article and Full-Text PDF